Industry reports
Editor highlights

Drug and Medication Industry Market Research Reports in Spain, April 2014

You might be interested in: drug, vaccine, medicine, more »

» View Public Reports

1-33 of 41 reports

Ear Care in Spain

  • Industry report
  • February 2013
  • 3 pages

The Ear Care in Spain CapsuleĀ provides headlines, market sizeĀ and competitive analysis alongside a set of charts including company shares, national brand owners and forecast...

  • Industries: Drug and Medication
  • Countries: Spain

Drug and Medication Sector in Spain

  • Industry report
  • June 2013
  • 23 pages

... Distributors, etc.) For placing medical devices on the market, and carrying out an efficient marketing surveillance. It also develops the system to strengthen controls on foreign trade, and prohibits ...

  • Industries: Drug and Medication
  • Countries: Spain

Spain: Brief Outlook, 2013, focus on Drug and Medication

  • Country report
  • February 2013
  • 5 pages

... And payer [20]. A canadian study showed that despite fingolimod having a greater reduc- tion in the annual relapse rate, it has the same net health benefit as treatment with interferon beta-1b [21 ...

  • Industries: Drug and Medication
  • Countries: Spain

Company Report: Drug and Medication in Spain for Year 2012

  • Company report
  • July 2012
  • 20 pages

... Rovi held a pre-ind meeting with the food and drug administration (fda) in order to get scientific advice on the drug development program of risperidone-ism . As planned, patients Enrolment ...

  • Industries: Drug and Medication
  • Countries: Spain

Drug and Medication Sector Analysis in The United States, Spain and Sweden

  • Industry report
  • July 2012
  • 74 pages
  • Industries: Drug and Medication
  • Countries: United States, Spain, Sweden

Company Report: Anti-cancer Drug in Spain for Year 2012

  • Company report
  • March 2012
  • 2 pages

... Zeltia s.A. Zeltia s.A. Is the largest biotechnology company in spain and the world leader in marine derived anti- cancer drugs. The group's principal activities are to manufacture bio ...

  • Industries: Drug and Medication
  • Countries: Spain

Company Report: Drug and Medication in Spain for Year 2012

  • Company report
  • March 2012
  • 18 pages
  • Industries: Drug and Medication
  • Countries: Spain

Company Report: Drug and Medication in Spain for Year 2012

  • Company report
  • March 2012
  • 18 pages

... The late preclinical phase. Initiation of the first human studies with paliperidone ism (another second generation antipsychotic drug) and letrozole ism (an aromatase inhibitor for the treatment ...

  • Industries: Drug and Medication
  • Countries: Spain

Company Report: Drug and Medication in Spain for Year 2012

  • Company report
  • March 2012
  • 60 pages

... Human studies with paliperidone ism (another second generation antipsychotic drug) and letrozole ism (an aromatase inhibitor for the treatment of breast cancer) are planned for the first halves ...

  • Industries: Drug and Medication
  • Countries: Spain

Company Report: Drug and Medication in Spain for Year 2012

  • Company report
  • March 2012
  • 19 pages

... Generation antipsychotic drug) and letrozole ism (an aromatase inhibitor for the treatment of breast cancer) are planned for the first halves of 2014 and 2015, respectively. 7. Key operating and financial ...

  • Industries: Drug and Medication
  • Countries: Spain

Ibuprofen Sector in Spain and Denmark

  • Industry report
  • February 2012
  • 8 pages
  • Industries: Drug and Medication
  • Countries: Spain, Denmark

The Spanish Drug and Medication Business Brief

  • Industry report
  • January 2012
  • 10 pages
  • by Research Paper

... Is presented. aspirin (asp) and acetaminophen (acph), as analgesic and antipyretic compounds, ibuprofen (ibu) and naproxen (nap), as nonsteroidal anti-inflammatory agents, and figure 1. Top: delos steps. Bottom ...

  • Industries: Drug and Medication
  • Countries: Spain

Drug and Medication Sector Analysis in China and Europe

  • Industry report
  • November 2011
  • 63 pages

... The proposed arrangements the government has stated that: i. I. There would be a basic threshold, reflecting the benefits displaced elsewhere in the nhs when funds are allocated to new medicines; ii. Ii ...

  • Industries: Drug and Medication
  • Countries: Spain, China, Europe

Vaccine in Europe and South Africa : Innovation and Technology Trends

  • Industry report
  • October 2011
  • 20 pages

... With hiv the potential of new tb vaccines a new, more effective tb vaccine could: Contribute significantly to global efforts to eliminate tb as a public health threat Be safer and more ...

  • Industries: Drug and Medication
  • Countries: Spain, Europe, South Africa

The European Drug and Medication Business Brief

  • Industry report
  • July 2011
  • 12 pages

... Aptivus (tipranavir - tpv) is a human immunodeficiency virus type 1 (hiv-1) protease inhibitor (pi), indicated in co-administration with low dose ritonavir (rtv, if used as booster =/r) for combination ...

  • Industries: Drug and Medication
  • Countries: Europe, United Kingdom, Spain

Company Report: Drug and Medication in The United States, Spain and India for Year 2011

  • Company report
  • March 2011
  • 2 pages

... Exchange, that the tablets are therapeutic equivalents of eli lilly's zyprexa zydis tablets. olanzapine tablets have an annual sale of about $360 million in the us, and are indicated in the treatment ...

  • Industries: Drug and Medication
  • Countries: United States, Spain, India

Drug and Medication Industry in The United States and Europe

  • Industry report
  • January 2011
  • 13 pages

... Of carbamazepine corresponds to dsstp sampling point 1 (67.7 Lglc01) (arroyo del bodonal, tres cantos), a waste-domi- nated stream (fig. 2). As remarked above, a technological industrial estate with pharmaceutical ...

  • Industries: Drug and Medication
  • Countries: Spain, United States, Europe

The Spanish Medicine Industry Analysis

  • Industry report
  • December 2010
  • 81 pages

... Pharmaceutical expenditure, nhs funds 75% of out- patient market and most of the hospital supply of medicines. The funds come from general taxes. Pricing, reimbursement and volume control in the out ...

  • Industries: Drug and Medication
  • Countries: Spain

Drug and Medication Market in Spain

  • Industry report
  • October 2010
  • 36 pages

... Consumption context, used doses, duration of the experience, drug source, simultaneous use with other drugs and satisfaction with the experience. Questionnaire ii: acute psychological effects ...

  • Industries: Drug and Medication
  • Countries: Spain

Drug Industry in Sweden, the United Kingdom and Spain

  • Industry report
  • May 2010
  • 6 pages

... Avonex * rebif * betaferon * tysabri. Comprehensive analysis of the global multiple sclerosis drug market global multiple sclerosis drug market 2010-2025 critically examines that sector through ...

  • Industries: Drug and Medication
  • Countries: Sweden, United Kingdom, Spain

Antibiotic in The United States and Spain : Innovation and Technology Trends

  • Industry report
  • May 2010
  • 262 pages

... Linked as the histories of 20th century anti- infective chemotherapy and the history of antibiotic resistance. Recent histories of sulfa- drugs and antibiotics have left no doubt that the arrival ...

  • Industries: Drug and Medication
  • Countries: United States, Spain

Spain: Country Brief, 2010, focus on Drug and Medication

  • Country report
  • February 2010
  • 11 pages
  • by Research Paper

... The market share of prescription drugs is 85.50% Of volume and 92% of total sales [3]. The average price of drugs in spain is low compared to that of other eu countries but, although regulated prices increase ...

  • Industries: Drug and Medication
  • Countries: Spain

Ibuprofen Sector in Spain

  • Industry report
  • January 2010
  • 6 pages
  • by Research Paper
  • Industries: Drug and Medication
  • Countries: Spain

Ibuprofen Market in Spain

  • Industry report
  • January 2010
  • 6 pages
  • by Research Paper
  • Industries: Drug and Medication
  • Countries: Spain

Drug and Medication Sector in Bulgaria, The United Kingdom and Spain

  • Industry report
  • October 2009
  • 28 pages

... To 90%), low level of education. Summarising . Differences between countries due to several factors (extent of problem drug use, referral routes, treatment availability, etc.) Increase in the number ...

  • Industries: Drug and Medication
  • Countries: Bulgaria, United Kingdom, Spain

Drug and Medication Sector in Spain

  • Industry report
  • July 2009
  • 16 pages
  • by Research Paper

... I. Moreno-torres et al. Name drugs are not protected by patents. The spanish pharmaceutical market is highly regulated since it has a regulation that caps the price of each medicine individually ...

  • Industries: Drug and Medication
  • Countries: Spain

Antipsychotic Drug Sector in Spain and Poland

  • Industry report
  • April 2009
  • 29 pages

... Clozapine (antipsychotic drug) march 2011 olanzapine (antipsychotic drug) 25th of april 2011 adamed products adamed products adamed products adamed products adamed products adamed: add- values services ...

  • Industries: Drug and Medication
  • Countries: Spain, Poland

Antipsychotic Drug Sector in Spain and Poland

  • Industry report
  • April 2009
  • 19 pages

... antipsychotic drug) 25 th of april 2011 adamed evolution since launch 151% 142% adamed spain A dream come true Focus on cns specialist with a high positioning with the kol of both societies. Recognised ...

  • Industries: Drug and Medication
  • Countries: Spain, Poland

Antipsychotic Drug Sector in Spain and Poland

  • Industry report
  • April 2009
  • 29 pages

... Antidepressant ) may 2009 pramipexole (antiparkinsonian drug) sept. 2010 Clozapine (antipsychotic drug) march 2011 olanzapine (antipsychotic drug) 25th of april 2011 adamed products adamed products adamed ...

  • Industries: Drug and Medication
  • Countries: Spain, Poland

Antipsychotic Drug Business in Spain and Poland

  • Industry report
  • April 2009
  • 19 pages

... Olanzapine (antipsychotic drug) 25th of april 2011 adamed evolution since launch 142% 151% adamed spain A dream come true Focus on cns specialist with a high positioning with the kol of both ...

  • Industries: Drug and Medication
  • Countries: Spain, Poland

The Spanish Drug and Medication Business Brief

  • Industry report
  • January 2009
  • 10 pages

... Compared to men. The options in these cases are very limited and the drugs available are not administered properly because patients often reach hospital more than 24 hours after an attack (the drugs ...

  • Industries: Drug and Medication
  • Countries: Spain

» Purchase Premium Reports (From $ 1 231 - $ 6 995)

About 100 reports
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic ...

Spain Vaccine Exports, Eurmn

January 2013 $ 250

Spain Vaccine Imports, Eurmn

January 2013 $ 250

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.